Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension

OBJECTIVE: Endothelin (ET) receptor antagonists (ERAs) have considerable improvements in pulmonary arterial hypertension (PAH) patients’ symptoms. Macitentan, a novel ERA, has more significant positive effects like reduction of morbidity and mortality in PAH patients by 45% and decreases PAH hospita...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Family Med Prim Care
Glavni autori: Nosrati, Marzieh, Shahmirzadi, Nikinaz Ashrafi, Afzali, Monireh, Zaboli, Pardis, Rouhani, Hasti, Hamedifar, Haleh, Hajimiri, Mirhamed
Format: Artigo
Jezik:Inglês
Izdano: Wolters Kluwer - Medknow 2020
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7567197/
https://ncbi.nlm.nih.gov/pubmed/33102342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/jfmpc.jfmpc_1166_19
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items